Doshi Medicare Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Doshi Medicare Private Limited Pharmaceutical Export Portfolio Dataset — 8 Products, $227.2K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Doshi Medicare Private Limited — Pharmaceutical Exporter Profile (2026) | 8 Products, $227.2K Trade | TransData Nexus

Doshi Medicare Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $227.2K Total Trade · DGFT Verified

Doshi Medicare Private Limited is an Indian pharmaceutical exporter with a total trade value of $227.2K across 8 products in 4 therapeutic categories. Based on 81 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Daratumumab ($98.7K), Rituximab ($55.6K), Gatifloxacin ($27.0K).

Doshi Medicare Private Limited — Export Portfolio & Destination Treemap

Doshi Medicare Private Limited pharmaceutical export portfolio — 8 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Doshi Medicare Private Limited? — Company Overview & Market Position

Doshi Medicare Private Limited, established on February 24, 2006, is a private unlisted company headquartered in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U51397MH2006PTC160027. Its authorized capital stands at ₹8.00 million, with a paid-up capital of ₹7.55 million. The registered office is located at Ground Floor, Manchram Building, Mayat Manzil, No. 344, S.V.P. Road, Girgaon, Mumbai, Maharashtra, 400044, India.

The company operates in the wholesale trade and commission trade sector, excluding motor vehicles and motorcycles, focusing on the distribution of pharmaceutical finished formulations. Doshi Medicare is part of the Doshi Group of Companies, a prominent entity in the pharmaceutical distribution industry in India. The group has been active since 1944, with Doshi Medicare serving as one of its flagship companies.

What Does Doshi Medicare Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Daratumumab$98.7K 2

Product Portfolio — Top 8 by Export Value

Doshi Medicare Private Limited exports 8 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Daratumumab	Advanced Oncology	$98.7K	23	7.4%	4
2	Rituximab	Advanced Oncology	$55.6K	14	0.3%	14
3	Gatifloxacin	Advanced Antibiotics	$27.0K	8	3.4%	3
4	Thalidomide	Advanced Oncology	$15.2K	9	0.8%	12
5	Nilotinib	Advanced Oncology	$13.9K	4	1.1%	4
6	Cladribine	Advanced Oncology	$8.5K	3	3.7%	6
7	Savlon	Brand Names & OTC Products	$6.7K	12	7.3%	3
8	Repaglinide	Advanced Diabetes Medications	$1.6K	8	0.0%	11

Doshi Medicare Private Limited exports 8 pharmaceutical products across 4 therapeutic categories with a total export value of $227.2K. The top category is Advanced Oncology (84.5% of portfolio), followed by Advanced Antibiotics (11.9%), indicating a concentrated portfolio with the top 5 products accounting for 92.6% of total export value.

Doshi Medicare Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Doshi Medicare Private Limited specializes in the distribution of pharmaceutical finished formulations, including tablets, capsules, syrups, and injections. The company does not operate its own manufacturing facilities; instead, it sources products from various manufacturers to meet the diverse needs of its clientele. This approach allows Doshi Medicare to offer a wide range of pharmaceutical products without the complexities associated with manufacturing operations. The company's distribution network is designed to efficiently deliver these products to healthcare providers, including hospitals, nursing homes, and government and private institutions.

3Key Leadership

The leadership team at Doshi Medicare Private Limited comprises several key individuals:

Mukesh Mahendrakumar Doshi: Director
Maitri Yogesh Doshi: Director
Hitesh Doshi Mukeshkumar: Managing Director
Yogesh Mukeshkumar Doshi: Managing Director
Surekha Mukeshkumar Doshi: Director
Hetal Hitesh Doshi: Director

These individuals play pivotal roles in steering the company's strategic direction and operations. Their collective experience and leadership contribute to Doshi Medicare's standing in the pharmaceutical distribution sector.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Doshi Medicare Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Doshi Medicare Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company has engaged in 81 shipments totaling $227,000 USD across eight products in four therapeutic categories. The top five exported products are:

Daratumumab: $99,000 USD, Rank #4, 7.4% market share
Rituximab: $56,000 USD, Rank #14, 0.3% market share
Gatifloxacin: $27,000 USD, Rank #3, 3.4% market share
Thalidomide: $15,000 USD, Rank #12, 0.8% market share
Nilotinib: $14,000 USD, Rank #4, 1.1% market share

The primary therapeutic categories for these exports are Advanced Oncology (84.5%), Advanced Antibiotics (11.9%), and Brand Names & OTC Products (3.0%). Notably, the company's portfolio concentration is high, with the top five products accounting for 92.6% of the total export value. This indicates a strategic focus on specific high-value products within the oncology and antibiotic segments.

Doshi Medicare Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of the latest available data, Doshi Medicare Private Limited has not reported any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), or Drug Master File (DMF) filings. This suggests that the company may not currently have direct market access to the United States. The absence of FDA approvals could be due to various factors, including the company's strategic focus on other markets or the complexity of obtaining FDA approvals for pharmaceutical products. Further engagement with the FDA and compliance with regulatory requirements would be necessary for market entry into the U.S.

2WHO & EU GMP

Doshi Medicare Private Limited's products are likely manufactured by third-party facilities that hold World Health Organization (WHO) Good Manufacturing Practice (GMP) certifications and European Union (EU) GMP certificates. While specific certifications for Doshi Medicare's products are not detailed, the company's focus on high-quality pharmaceutical formulations suggests adherence to international manufacturing standards. Ensuring that manufacturing partners maintain WHO and EU GMP certifications is essential for maintaining product quality and meeting regulatory requirements in various markets.

CDSCO & Indian Regulatory

Doshi Medicare Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Doshi Medicare Private Limited operates in a competitive pharmaceutical distribution market, facing competition from both domestic and international players. Key competitors include AmerisourceBergen, Entero Healthcare, Keimed, Sandor Medicaids, and Mahaveer Medi Sales. These companies offer similar product portfolios and distribution services, intensifying the competitive dynamics. Doshi Medicare's focus on high-demand therapeutic areas, such as oncology and antibiotics, positions it strategically within the market. However, the company's high portfolio concentration in a few products may limit its ability to compete across a broader range of therapeutic categories.

2Key Differentiators

Doshi Medicare Private Limited's key differentiators include its longstanding presence in the pharmaceutical distribution industry, being part of the Doshi Group established in 1944. The company's specialization in distributing finished pharmaceutical formulations, including oncology and antibiotic products, caters to specific market needs. Additionally, Doshi Medicare's focus on high-quality products and adherence to international manufacturing standards enhance its credibility and appeal to healthcare providers. However, the company's high portfolio concentration in a few products may limit its ability to offer a diversified range of therapeutic options.

Strategic Position

Buyer Due Diligence Brief — Evaluating Doshi Medicare Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Doshi Medicare Private Limited's track record in pharmaceutical distribution is characterized by a focus on high-quality finished formulations. The company's export volume and consistency indicate a reliable supply chain and operational efficiency. However, the high concentration of export value in a few products suggests a need for diversification to mitigate potential risks associated with over-reliance

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Doshi Medicare Private Limited

How many pharmaceutical products does Doshi Medicare Private Limited export from India?

Doshi Medicare Private Limited exports 8 pharmaceutical products across 4 therapeutic categories. The top exports are Daratumumab ($98.7K), Rituximab ($55.6K), Gatifloxacin ($27.0K), Thalidomide ($15.2K), Nilotinib ($13.9K). Total export value is $227.2K.

What is Doshi Medicare Private Limited's total pharmaceutical export value?

Doshi Medicare Private Limited's total pharmaceutical export value is $227.2K, based on 81 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Doshi Medicare Private Limited cover?

Doshi Medicare Private Limited exports across 4 therapeutic categories. The largest are Advanced Oncology (84.5%, 5 products), Advanced Antibiotics (11.9%, 1 products), Brand Names & OTC Products (3.0%, 1 products).

Get Full Doshi Medicare Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.